Clinical Trials Browser

Phase 1/2 × Active not recruiting × Urinary Bladder Neoplasms × Clear all

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

369 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

702 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06305767 2026-01-13

INTerpath-005

Phase 1/2 Active not recruiting

230 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

310 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

54 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Phase 1/2 Active not recruiting

46 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04180371 2025-11-17

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1/2 Active not recruiting

288 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04561362 2025-11-14

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase 1/2 Active not recruiting

329 enrolled

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Renal Insufficiency, Triple Negative Breast Neoplasms

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

98 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1/2 Active not recruiting

81 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04046094 2025-03-25

Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Phase 1/2 Active not recruiting

12 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms

NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Phase 1/2 Active not recruiting

25 enrolled

Genitourinary

Urinary Bladder Neoplasms